Most Read Articles
29 Nov 2017
Rapid onset opioids may allow for more effective treatment of breakthrough cancer pain as their pharmacokinetic profile closely mimics the pain’s time course
Christina Lau, 22 Oct 2015
A 21-gene expression assay can identify patients with early-stage breast cancer who can skip adjuvant chemotherapy without facing an increased risk of recurrence at 5 years.
Elvira Manzano, 13 Sep 2017
Tisagenlecleucel, now US FDA approved, has made history as the first ever chimeric antigen receptor (CAR) T-cell therapy for B-cell precursor acute lymphoblastic leukaemia (ALL) – a breakthrough that has the potential to transform treatment for blood cancers that have not responded to standard therapies.
Naomi Adam, 01 Apr 2014

Colorectal cancer (CRC) is one of the most common cancers worldwide and its incidence is rising among Asians. Long-term survival outcomes are poor for CRC because patients often remain undiagnosed until the disease has reached an advanced stage. Panitumumab, a human IgG2 monoclonal antibody with high binding affinity for epidermal growth factor receptors, has shown encouraging results in the treatment of metastatic CRC (mCRC).

Albumin-bilirubin grade predicts prognosis in HCC

06 Jul 2017

Albumin-bilirubin (ALBI) grade may predict prognosis in hepatocellular carcinoma (HCC) patients undergoing transarterial chemoembolization (TACE), a new study shows.

The study included 881 HCC patients receiving TACE (median age 68 years; 76 percent male) and showing a median overall survival of 24 months. Hepatitis B (35 percent, n=311) and C (27 percent; n=241), and alcoholism (19 percent; n=162) were the principal causes of HCC.

Of all the tested markers, ALBI grade resulted in the highest homogeneity (43.655) and lowest corrected Akaike information criteria (AICc) value (8,094.296). This was followed by cirrhosis discriminant index (CDS; 35.635 and 8,102.143, respectively) and Child-Turcotte-Pugh score (CTP; 26.861 and 8,111.090, respectively).

Univariate survival analysis showed that alcoholism (hazard ratio [HR], 1.240; 95 percent CI, 1.018 to 1.509; p=0.032), alkaline phosphatase level (HR, 1.678; 1.435 to 1.963; p<0.001), vascular invasion (HR, 2.511; 2.075 to 3.039; p<0.001) and ALBI grades 2 (HR, 1.678; 1.421 to 1.981; p<0.001) and 3 (HR, 1.501; 1.251 to 1.801; p<0.001) were all indicators of poor prognosis.

Multivariate analysis confirmed the significant association of alkaline phosphatase level (HR, 1.362; 1.155 to 1.607; p<0.001), vascular invasion (HR, 1.999; 1.622 to 2.464; p<0.001) and ALBI grade 2 (HR, 1.531; 1.285 to 2.823; p<0.001) to reduced survival.

ALBI grade 3 (HR, 1.525; 0.976 to 2.382l; p=0.064) was only modestly associated with poor survival.

Participants with histologically confirmed HCC were recruited from the Taipei Veterans General Hospitals.

Aside from ALBI, CTP and CDS, the prognostic performances of the following liver reserve markers were also assessed: aspartate transaminase-to-platelet ratio (APRI), fibrosis index based on four factors (FIB-4), Göteborg University Cirrhosis Index (GUCI), model for end-stage liver disease (MELD) and Lok index.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
29 Nov 2017
Rapid onset opioids may allow for more effective treatment of breakthrough cancer pain as their pharmacokinetic profile closely mimics the pain’s time course
Christina Lau, 22 Oct 2015
A 21-gene expression assay can identify patients with early-stage breast cancer who can skip adjuvant chemotherapy without facing an increased risk of recurrence at 5 years.
Elvira Manzano, 13 Sep 2017
Tisagenlecleucel, now US FDA approved, has made history as the first ever chimeric antigen receptor (CAR) T-cell therapy for B-cell precursor acute lymphoblastic leukaemia (ALL) – a breakthrough that has the potential to transform treatment for blood cancers that have not responded to standard therapies.
Naomi Adam, 01 Apr 2014

Colorectal cancer (CRC) is one of the most common cancers worldwide and its incidence is rising among Asians. Long-term survival outcomes are poor for CRC because patients often remain undiagnosed until the disease has reached an advanced stage. Panitumumab, a human IgG2 monoclonal antibody with high binding affinity for epidermal growth factor receptors, has shown encouraging results in the treatment of metastatic CRC (mCRC).